How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,595 results for

Intrauterine Device

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Chronic Systemic Toxicity Study of Copper Intrauterine Devices in Female Wistar Rats (PubMed)

Chronic Systemic Toxicity Study of Copper Intrauterine Devices in Female Wistar Rats BACKGROUND The aim of this study was to evaluate the chronic systemic and local toxicity of a copper intrauterine device in a rat model. MATERIAL AND METHODS Cu-IUD fragments were inserted into the uterine horns of female Wistar rats for 26 weeks (equivalent 15.42-17.33 years in humans). We tested copper at 20, 40, and 60 times the clinical dosages to study copper toxicity under severe conditions. Classic

Full Text available with Trip Pro

2017 Medical science monitor : international medical journal of experimental and clinical research

142. Visibility of Strings After Postplacental Intracesarean Insertion of CuT380A and Cu375 Intrauterine Contraceptive Device: A Randomized Comparative Study (PubMed)

Visibility of Strings After Postplacental Intracesarean Insertion of CuT380A and Cu375 Intrauterine Contraceptive Device: A Randomized Comparative Study To compare the incidence of visible strings after postplacental intracesarean insertion of Cu375 and CuT380A intrauterine contraceptive devices (IUD).This was a prospective, randomized comparative study. A total of 100 women fulfilling the inclusion and exclusion criteria underwent postplacental intracesarean insertion of either Cu375 IUD

Full Text available with Trip Pro

2017 Journal of obstetrics and gynaecology of India

143. Correction to: Trends in use of and complications from intrauterine contraceptive devices and tubal ligation or occlusion (PubMed)

Correction to: Trends in use of and complications from intrauterine contraceptive devices and tubal ligation or occlusion 28985748 2018 11 13 1742-4755 14 1 2017 10 06 Reproductive health Reprod Health Correction to: Trends in use of and complications from intrauterine contraceptive devices and tubal ligation or occlusion. 126 10.1186/s12978-017-0386-2 Howard Brandon B Teva Global Medical Affairs, 41 Moores Road, Frazer, PA, 19355, USA. Brandihoward@gmail.com. Grubb ElizaBeth E Teva Global

Full Text available with Trip Pro

2017 Reproductive health

144. A large bladder stone caused by the intravesical migration of an intrauterine contraceptive device: a case report (PubMed)

A large bladder stone caused by the intravesical migration of an intrauterine contraceptive device: a case report A wide variety of complications due to the extrauterine migration of intrauterine contraceptive devices have been reported in the literature. Here we describe the case of a large bladder stone formed around a migrated Copper T380A device that was neglected and detected 15 years after insertion.A 48-year-old Sri Lankan woman underwent a workup for lower urinary tract symptoms (...) and recurrent urinary tract infections over the previous 6 months. The radiographs showed a large bladder stone with an imprint of an intrauterine contraceptive device in the center of it. The device had been inserted 15 years previously. Two years after the insertion, it was considered to be missing, but our patient did not comply with the recommended follow-up. She had been completely asymptomatic until she developed lower urinary tract symptoms. After confirming the location of the stone via

Full Text available with Trip Pro

2017 Journal of medical case reports

145. Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management (PubMed)

Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management Globally, endometrial cancer is the sixth leading cause of female cancer-related deaths. Non-atypical endometrial hyperplasia (EH), has a lifetime progression rate to endometrial cancer ranging from less than 5%, if simple without atypia, to 40%, if complex with atypia. Site specific, long-acting intrauterine devices (IUDs) provide fertility sparing, progestin-based EH

Full Text available with Trip Pro

2017 Healthcare

146. Two-year continuation of intrauterine devices and contraceptive implants in a mixed-payer setting: A retrospective review. (PubMed)

Two-year continuation of intrauterine devices and contraceptive implants in a mixed-payer setting: A retrospective review. As the popularity of long-acting reversible contraception increases, so does the need for accurate data on method continuation in diverse clinical settings. We determined 2-year continuation rates for the levonorgestrel 52-mg intrauterine device, the copper T380A intrauterine device, and the 68-mg etonogestrel contraceptive implant in an academic healthcare system (...) with mixed-payer reimbursement.The purpose of this study was to examine the proportion and characteristics of women who continue intrauterine device and implant use to 2 years and to relate continuation to device type when controlling for patient characteristics.This retrospective chart review assessed University of Utah Healthcare System patients who had an intrauterine device or contraceptive implant inserted between January 1, 2004, and December 31, 2012. We identified users and dates of insertions

Full Text available with Trip Pro

2017 American Journal of Obstetrics and Gynecology

147. New Product Review: Intrauterine Ball (IUB) SCu300B MIDI

, the Intrauterine Ball (IUB™) SCu300B MIDI is a copper intrauterine device (Cu-IUD) comprised of copper beads with a total exposed copper surface of 300mm² strung on a flexible Nitinol (nickel/titanium alloy), PET-coated frame. Once the IUB is released from the 3.2mm diameter insertion tube into the uterus it coils into a spherical shape measuring 15mm in diameter. Download the product review in full here. Your download should start automatically. If not . Thinking about taking a qualification? Registration (...) New Product Review: Intrauterine Ball (IUB) SCu300B MIDI New Product Review: Intrauterine Ball (IUB™) SCu300B MIDI - February 2019 - Faculty of Sexual and Reproductive Healthcare New Product Review: Intrauterine Ball (IUB™) SCu300B MIDI - February 2019 New Product Review: Intrauterine Ball (IUB™) SCu300B MIDI - February 2019 Share this article 270def2e962ad577f33833df3d701209 Published on: 11 February 2019 File size: 252kb PDF File type: New Product Reviews Manufactured by OCON Medical Ltd

2019 Faculty of Sexual & Reproductive Healthcare

148. Adolescents and Long-Acting Reversible Contraception: Implants and Intrauterine Devices

Adolescents and Long-Acting Reversible Contraception: Implants and Intrauterine Devices Adolescents and Long-Acting Reversible Contraception: Implants and Intrauterine Devices - ACOG Menu ▼ Adolescents and Long-Acting Reversible Contraception: Implants and Intrauterine Devices Page Navigation ▼ Number 735, May 2018 (Replaces Committee Opinion Number 539, October 2012) Committee on Adolescent Health Care Long-Acting Reversible Contraception Work Group This Committee Opinion was developed (...) : Implants and Intrauterine Devices ABSTRACT: The phenomenon of adolescent childbearing is complex and far reaching, affecting not only the adolescents but also their children and their community. The prevalence and public health effect of adolescent pregnancy reflect complex structural social problems and an unmet need for acceptable and effective contraceptive methods in this population. In 2006–2010, 82% of adolescents at risk of unintended pregnancy were currently using contraception, but only 59

2012 American College of Obstetricians and Gynecologists

149. Levonorgestrel-Releasing Intrauterine System 52 mg for Idiopathic Heavy Menstrual Bleeding

Technology Advisory Committee recommends publicly funding the 52-mg levonorgestrel-releasing intrauterine system for the treatment of idiopathic heavy menstrual bleeding Heavy menstrual bleeding can be painful, distressing and disruptive. Up to one-third of women between the ages of 15 and 55 experience heavy menstrual bleeding, and often the cause is unknown. However, treatment can reduce the symptoms and improve quality of life. Some options include medications, surgery, and a device called (...) the levonorgestrel-releasing intrauterine system. Health Quality Ontario Reviews the Levonorgestrel-Releasing Intrauterine System for Heavy Menstrual Bleeding The levonorgestrel-releasing intrauterine system is a minimally invasive and reversible device that is inserted in the uterus where it releases a hormone that suppresses and thins the lining of the uterus (endometrium), which can result in a reduction in the amount of bleeding. Currently, the insertion procedure is publicly funded in Ontario but the cost

2017 Health Quality Ontario

150. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices. (PubMed)

Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices. The objective was to measure the rate of unintended pregnancies in women using levonorgestrel-releasing intrauterine systems (LNG IUSs, releasing 20 mcg LNG daily) and copper intrauterine devices (IUDs) in a typical population of IUD users and to describe associated complications.A multinational, prospective, non-interventional

Full Text available with Trip Pro

2015 Contraception

151. Risk of Uterine Perforation with Levonorgestrel-Releasing and Copper Intrauterine Devices in the European Active Surveillance Study on Intrauterine Devices. (PubMed)

Risk of Uterine Perforation with Levonorgestrel-Releasing and Copper Intrauterine Devices in the European Active Surveillance Study on Intrauterine Devices. The objectives were to identify and compare the incidence of uterine perforation and other medically adverse events associated with levonorgestrel-releasing intrauterine systems (LNG-IUSs, releasing 20 mcg LNG daily) and copper intrauterine devices (IUDs) under routine conditions of use in a study population representative of typical (...) -three of the total 81 perforations were associated with previously suspected risk factors (e.g., breastfeeding, time since last delivery ≤36 weeks). No perforations led to serious illness or to injury of intra-abdominal or pelvic structures.Uterine perforation incidence in this study was low, with a benign clinical course thereafter. The LNG-IUSs and copper IUDs did not have clinically important differences in perforation rates.The European Active Surveillance Study on Intrauterine Devices

Full Text available with Trip Pro

2015 Contraception

152. Effects of the levonorgestrel-releasing intrauterine device on the immune microenvironment of the human cervix and endometrium (PubMed)

Effects of the levonorgestrel-releasing intrauterine device on the immune microenvironment of the human cervix and endometrium There is little information regarding the impact of the intrauterine device on immune parameters of the upper female reproductive tract related to risk of HIV acquisition.We collected cervical and endometrial samples from women using the hormonal intrauterine device to study its effects on endocervical cytokines/chemokine concentrations, phenotypic markers of T cells (...) , responses of endometrial T cells to activation, and alterations of endometrial cellular infiltrates.Hormonal intrauterine device use was associated with: increased concentrations of inflammatory cytokines/chemokines (endocervix); increased coexpression of CXCR4 and CCR5 (endocervix and endometrium); increased coexpression of CD38 and HLADR (endocervix and endometrium); increased intracellular IL-10 production after T-cell stimulation (endometrium); and increased density of T cells, most notably

Full Text available with Trip Pro

2016 American journal of reproductive immunology (New York, N.Y. : 1989)

153. Immediate Postpartum Intrauterine Contraceptive Device Insertions in Caesarean and Vaginal Deliveries: A Comparative Study of Follow-Up Outcomes (PubMed)

Immediate Postpartum Intrauterine Contraceptive Device Insertions in Caesarean and Vaginal Deliveries: A Comparative Study of Follow-Up Outcomes Background. Immediate postpartum intrauterine contraceptive device (IPPIUCD) is a lucrative postpartum family planning method which provides effective reversible contraception to women in the delivery setting. Our aim was to study the clinical outcomes of IPPIUCD insertions and compare them as a factor of route of insertion (vaginal versus caesarean

Full Text available with Trip Pro

2016 International journal of reproductive medicine

154. Migration of an intrauterine device to the left inguinal region, the first reported case (PubMed)

Migration of an intrauterine device to the left inguinal region, the first reported case A large number of complications are reported with the use of IUD. Migration to inguinal region has not been mentioned in literature. We report a rare case of migrated IUD to inguinal canal.A 25-year-old lady presented with a painfull mass in the left inguinal region. Diagnostic work up showed migrated IUD to inguinal region. Operation was done and the impacted IUD with surrounding granuloma

Full Text available with Trip Pro

2016 International journal of surgery case reports

155. Corrigendum to "Rowe P et al. safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A" [Contraception 2016;93:498-506]. (PubMed)

Corrigendum to "Rowe P et al. safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A" [Contraception 2016;93:498-506]. 27312266 2018 11 13 1879-0518 94 3 2016 Sep Contraception Contraception Corrigendum to "Rowe P et al. safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A" [Contraception 2016;93:498-506]. 288

Full Text available with Trip Pro

2016 Contraception

156. Translocation of Postplacental Intrauterine Device: A Rare Complication (PubMed)

Translocation of Postplacental Intrauterine Device: A Rare Complication 27803550 2018 11 13 0971-9202 66 Suppl 2 2016 10 Journal of obstetrics and gynaecology of India J Obstet Gynaecol India Translocation of Postplacental Intrauterine Device: A Rare Complication. 707-709 Mishra Sujnanendra S 0000-0003-1003-9884 Balangir, Odisha India. eng Journal Article 2016 04 27 India J Obstet Gynaecol India 0374763 0975-6434 The authors declare that there are no competing interests. Ethical Statement

Full Text available with Trip Pro

2016 Journal of obstetrics and gynaecology of India

157. Is There Any Impact of Copper Intrauterine Device on Female Sexual Functioning? (PubMed)

Is There Any Impact of Copper Intrauterine Device on Female Sexual Functioning? Intrauterine Device (IUD) is the most preferred modern contraceptive method in Turkey. Female Sexual Dysfunction (FSD) is defined as lack of one or more of the components in the sexual response cycle which includes sexual desire, impaired arousal and inability achieving an orgasm or pain with intercourse. FSD has multi-factorial aetiology. Advanced age and menopause, fatigue and stress, psychiatric and neurologic

Full Text available with Trip Pro

2016 Journal of clinical and diagnostic research : JCDR

158. Evaluation of a Novel and Simplified Technique for Intrauterine Contraceptive Devices Insertion: a Prospective Cohort Study

Evaluation of a Novel and Simplified Technique for Intrauterine Contraceptive Devices Insertion: a Prospective Cohort Study Evaluation of a Novel and Simplified Technique for Intrauterine Contraceptive Devices Insertion: a Prospective Cohort Study - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Evaluation of a Novel and Simplified Technique for Intrauterine Contraceptive Devices Insertion: a Prospective Cohort Study The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02841826 Recruitment Status

2016 Clinical Trials

159. Evaluation of a Novel Technique for Intrauterine Contraceptive Devices Insertion

Evaluation of a Novel Technique for Intrauterine Contraceptive Devices Insertion Evaluation of a Novel Technique for Intrauterine Contraceptive Devices Insertion - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Evaluation of a Novel Technique for Intrauterine Contraceptive Devices Insertion The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02842177 Recruitment Status : Completed First Posted : July 22, 2016 Last Update Posted : March 28, 2017 Sponsor: Assiut University Information provided

2016 Clinical Trials

160. Cold Compress for Pain Associated With Intrauterine Device Insertion

Cold Compress for Pain Associated With Intrauterine Device Insertion Cold Compress for Pain Associated With Intrauterine Device Insertion - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Cold Compress (...) for Pain Associated With Intrauterine Device Insertion The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02898831 Recruitment Status : Completed First Posted : September 13, 2016 Last Update Posted : March 18, 2019 Sponsor: Virginia Commonwealth University Information provided by (Responsible Party

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>